Proteo Biotech AG
Proteo, Inc. / Proteo Biotech AG: Novel Anti-inflammatory Mechanism of Elafin
Corporate News transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
——————————————————————————
Irvine, CA / Kiel, December 11, 2006 – Proteo, Inc. (OTCBB: PTEO; WKN:
925981) and its wholly-owned subsidiary Proteo Biotech AG announced today:
The team of Prof. Noel McElvaney at the Respiratory Research Division,
Royal College of Surgeons in Dublin, is focused on the research in the
field of inflammatory pulmonary diseases, particularly of cystic fibrosis.
The team has shown that Elafin is able to abrogate
lipopolysaccharide-induced production of monocyte chemotactic protein 1 in
monocytes by inhibiting AP-1 and NFkappaB activation. The authors conclude
that due to its selective expression at mucosal surfaces as well as in
alveolar macrophages, monocytes and neutrophils, the ability of Elafin to
inhibit the lipopolysaccharide signaling pathway may be important in
disease states such as cystic fibrosis, pneumonia, and acute respiratory
distress syndrome. The inhibition of two key inflammatory pathways confirms
the importance of Elafin as a mediator of the innate immune response.
Source: Butler MW, Robertson I, Greene CM, O’Neill SJ, Taggart CC,
McElvaney NG. Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB
activation via an effect on the ubiquitin-proteasome pathway. J Biol Chem.
2006; 281: 34730-5.
Prof. Oliver Wiedow, Chairman of the Board, Proteo, Inc.: »These results
are a major breakthrough in our understanding of the anti-inflammatory
properties of Elafin. In addition to the known effects of Elafin in
preventing tissue degradation during inflammation this novel
anti-inflammatory mechanism of Elafin may contribute to its potential
efficacy in the treatment of inflammatory lung diseases in which infections
play a major role.«
About Elafin
Elafin is a protein that is produced naturally in the skin, lung and
breast, protecting the respective tissue from destruction by the immune
system. Elafin´s ability to block the activity of destructive enzymes that
are involved in inflammatory reactions makes it a highly promising active
compound for the treatment of inflammatory lung diseases or severe
reperfusion injuries occurring after heart attacks, serious injuries and
organ transplantation. The excellent tolerability of Elafin in human
subjects was demonstrated in a Phase I clinical single dose escalating
study.
About Proteo
PROTEO Biotech AG, based in Kiel, Germany was founded in April 2000 and in
the same year was taken over by the US-American holding company PROTEO Inc.
The company researches, develops and markets compounds for biological and
medical research as well as for use as pharmaceuticals. PROTEO holds the
production and utilization rights for recombinant human Elafin. PROTEO
intends to out-license selected indications and to establish international
strategic alliances in order to open up new fields of application and for
marketing. The federal state of Schleswig-Holstein funds the innovative
development venture of PROTEO Biotech AG with money from the European Fund
for Regional Development (EFRE).
Forward-Looking Statements
Certain statements in this news release may contain forward-looking
information within the meaning of Rule 175 under the Securities Act of 1933
and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to
the safe harbor created by those rules. All statements, other than
statements of fact included in this release, including, without limitation,
statements regarding potential future plans and objectives of the company,
are forward-looking statements that involve risks and uncertainties. There
can be no assurance that such statements will prove to be accurate and
actual results and future events could differ materially from those
anticipated in such statements. Technical complications that may arise
could prevent the prompt implementation of any strategically significant
plan(s) outlined above. The company cautions that these forward looking
statements and risks and uncertainties involved are further qualified by
other factors including, but not limited to those set forth in the
company’s Form 10-KSB filing and other filings with the United States
Securities and Exchange Commission. The company undertakes no obligation to
publicly update or revise any statements in this release, whether as a
result of new information, future events or otherwise.
Contact:
Dr. Barbara Kahlke
Proteo Biotech AG
Am Kiel-Kanal 44
D-24106 Kiel
Email : info@proteo.de
Telefon: +49(0)431 8888462
Fax : +49(0)431 8888463
(c)DGAP 11.12.2006
—————————————————————————
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found